Review



human osteosarcoma cell line 143b  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC human osteosarcoma cell line 143b
    Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of <t>143B</t> Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).
    Human Osteosarcoma Cell Line 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1407 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteosarcoma cell line 143b/product/ATCC
    Average 97 stars, based on 1407 article reviews
    human osteosarcoma cell line 143b - by Bioz Stars, 2026-06
    97/100 stars

    Images

    1) Product Images from "Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma"

    Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

    Journal: Drug Delivery

    doi: 10.1080/10717544.2026.2671485

    Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of 143B Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).
    Figure Legend Snippet: Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of 143B Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).

    Techniques Used: WST-1 Assay, Standard Deviation, Immunofluorescence, Staining, Control

    Cytotoxic effect of organometallic compounds in 3D parental spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B Par (A and B) and OS833 Par (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B Par (A) and OS833 Par (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Likewise, cell survival curves and IC50 values (µM) for each condition in 143B Par (B) and OS833 Par (D) spheroids are presented as the mean ± the standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test).
    Figure Legend Snippet: Cytotoxic effect of organometallic compounds in 3D parental spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B Par (A and B) and OS833 Par (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B Par (A) and OS833 Par (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Likewise, cell survival curves and IC50 values (µM) for each condition in 143B Par (B) and OS833 Par (D) spheroids are presented as the mean ± the standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test).

    Techniques Used: Standard Deviation

    Cytotoxic effect of organometallic compounds in 3D cisplatin-resistant spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B CisPt-R (A and B) and OS833 CisPt-R (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B CisPt-R (A) and OS833 CisPt-R (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Cell survival curves and IC50 values (µM) for each condition in 143B CisPt-R (B) and OS833 CisPt-R (D) are presented as the mean ± standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (* p < 0.05; ** p < 0.01; **** p < 0.0001; two-way ANOVA Tukey's test).
    Figure Legend Snippet: Cytotoxic effect of organometallic compounds in 3D cisplatin-resistant spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B CisPt-R (A and B) and OS833 CisPt-R (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B CisPt-R (A) and OS833 CisPt-R (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Cell survival curves and IC50 values (µM) for each condition in 143B CisPt-R (B) and OS833 CisPt-R (D) are presented as the mean ± standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (* p < 0.05; ** p < 0.01; **** p < 0.0001; two-way ANOVA Tukey's test).

    Techniques Used: Standard Deviation

    Effect of free and nano-encapsulated Ru3 in CSC-enriched 3D osteosarcoma cell cultures. 143B Par cells were plated at low density in tumorsphere medium and left to form tumorspheres for 9 days before being treated for 96 h with increasing concentrations of Ru3, LIP-Ru3, and cisplatin. Treatments with the same amount of empty nanoparticles (LIP-Empty) were also included. Representative images (scale bars = 250 μm) (A), quantification of the number of tumorspheres remaining after the treatment (B), and cell viability (WST-1 assay) (C) are presented. Data is presented as the mean ± the standard deviation of independent replicates. In panel B, black asterisks indicate statistically significant differences between controls and the indicated conditions in each treatment. In panel C, asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon); (** p < 0.01; *** p < 0.001; one-way (panel B) or two-way (panel C) ANOVA Tukey's test).
    Figure Legend Snippet: Effect of free and nano-encapsulated Ru3 in CSC-enriched 3D osteosarcoma cell cultures. 143B Par cells were plated at low density in tumorsphere medium and left to form tumorspheres for 9 days before being treated for 96 h with increasing concentrations of Ru3, LIP-Ru3, and cisplatin. Treatments with the same amount of empty nanoparticles (LIP-Empty) were also included. Representative images (scale bars = 250 μm) (A), quantification of the number of tumorspheres remaining after the treatment (B), and cell viability (WST-1 assay) (C) are presented. Data is presented as the mean ± the standard deviation of independent replicates. In panel B, black asterisks indicate statistically significant differences between controls and the indicated conditions in each treatment. In panel C, asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon); (** p < 0.01; *** p < 0.001; one-way (panel B) or two-way (panel C) ANOVA Tukey's test).

    Techniques Used: WST-1 Assay, Standard Deviation

    In vivo antitumor effect of free and nanoencapsulated metallic compounds. Established 143B CisPt-R xenografts were randomly assigned to six different groups ( n = 5 per group) and treated i.v. with vehicle (PBS, control), empty liposomes (LIP-Empty), free Ru3 (4 mg/kg, Ru3), ruthenium-loaded liposomes (4 mg/kg, LIP-Ru3), RAPTA-C (4 mg/kg), and cisplatin (4 mg/kg) once a week for 3 weeks (cumulative dose of 12 mg/kg). (A) Curves representing the mean relative tumor volume of 143B CisPt-R xenografts during the treatments. Drug efficacy expressed as the percentage of TGI is indicated. (B) Average tumor weight (left panel) and images of the tumors (right panel) at the end of the experiment (day 20 after the start of the treatment). (C) Change in the body weights of mice during the treatments. Error bars represent the SEM and asterisks indicate statistically significant differences between groups (* p < 0.05; **** p < 0.0001, two-way ANOVA Tukey's test).
    Figure Legend Snippet: In vivo antitumor effect of free and nanoencapsulated metallic compounds. Established 143B CisPt-R xenografts were randomly assigned to six different groups ( n = 5 per group) and treated i.v. with vehicle (PBS, control), empty liposomes (LIP-Empty), free Ru3 (4 mg/kg, Ru3), ruthenium-loaded liposomes (4 mg/kg, LIP-Ru3), RAPTA-C (4 mg/kg), and cisplatin (4 mg/kg) once a week for 3 weeks (cumulative dose of 12 mg/kg). (A) Curves representing the mean relative tumor volume of 143B CisPt-R xenografts during the treatments. Drug efficacy expressed as the percentage of TGI is indicated. (B) Average tumor weight (left panel) and images of the tumors (right panel) at the end of the experiment (day 20 after the start of the treatment). (C) Change in the body weights of mice during the treatments. Error bars represent the SEM and asterisks indicate statistically significant differences between groups (* p < 0.05; **** p < 0.0001, two-way ANOVA Tukey's test).

    Techniques Used: In Vivo, Control, Liposomes



    Similar Products

    human osteosarcoma cell line 143b  (ATCC)
    97
    ATCC human osteosarcoma cell line 143b
    Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of <t>143B</t> Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).
    Human Osteosarcoma Cell Line 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteosarcoma cell line 143b/product/ATCC
    Average 97 stars, based on 1 article reviews
    human osteosarcoma cell line 143b - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    human osteosarcoma cell lines  (ATCC)
    95
    ATCC human osteosarcoma cell lines
    (A) 143B cells <t>(osteosarcoma)</t> show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.
    Human Osteosarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteosarcoma cell lines/product/ATCC
    Average 95 stars, based on 1 article reviews
    human osteosarcoma cell lines - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    human osteosarcoma cells  (ATCC)
    97
    ATCC human osteosarcoma cells
    (A) 143B cells <t>(osteosarcoma)</t> show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.
    Human Osteosarcoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteosarcoma cells/product/ATCC
    Average 97 stars, based on 1 article reviews
    human osteosarcoma cells - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    143b human osteosarcoma cell line  (ATCC)
    97
    ATCC 143b human osteosarcoma cell line
    (A) 143B cells <t>(osteosarcoma)</t> show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.
    143b Human Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/143b human osteosarcoma cell line/product/ATCC
    Average 97 stars, based on 1 article reviews
    143b human osteosarcoma cell line - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    human osteosarcoma cell lines 143b  (ATCC)
    97
    ATCC human osteosarcoma cell lines 143b
    (A) 143B cells <t>(osteosarcoma)</t> show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.
    Human Osteosarcoma Cell Lines 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteosarcoma cell lines 143b/product/ATCC
    Average 97 stars, based on 1 article reviews
    human osteosarcoma cell lines 143b - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    human osteosarcoma cells 143b  (ATCC)
    97
    ATCC human osteosarcoma cells 143b
    (A) 143B cells <t>(osteosarcoma)</t> show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.
    Human Osteosarcoma Cells 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human osteosarcoma cells 143b/product/ATCC
    Average 97 stars, based on 1 article reviews
    human osteosarcoma cells 143b - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of 143B Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).

    Journal: Drug Delivery

    Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

    doi: 10.1080/10717544.2026.2671485

    Figure Lengend Snippet: Antitumor effect of organometallic compounds in osteosarcoma cell lines. Cell viability (WST-1 assay) in 2D cultures measured after the treatment of 143B Par (A), OS833 Par (B), 143B CisPt-R (C), and OS833 CisPt-R (D) with increasing concentrations of free or encapsulated drugs for 72 h. The effect of equivalent amounts of empty nanoparticles in each cell line is shown. IC 50 values for each treatment are indicated. Error bars represent the standard deviation of three independent experiments. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test). (E and F) Analysis of DNA damage (formation of −H2AX foci) in 143B CisPt-R cells treated with the IC 75 of CisPt (8.4 µM), Ru3 (0.9 µM), LIP-Ru3 (0.8 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 24 hours. Representative images of immunofluorescence staining (scale bar = 25 µm) (E) and quantification of the formation of gH2AX foci in >100 cells (F) are shown. Asterisks indicate statistically significant differences (** p < 0.01; *** p < 0.001; One-way ANOVA Tukey's test). (G) Cell cycle distribution of 143B CisPt-R cells treated with the IC 50 of CisPt (5 µM), Ru3 (0.5 µM), LIP-Ru3 (0.5 µM), or the equivalent amount of empty nanoparticles (LIP-Empty) for 48 hours. The normalized percentage of cells in each cell cycle phase (mean ± standard deviation of three independent experiments) is shown. Asterisks indicate statistically significant differences in G 0 /G 1 phase (blue) between LIP-empty control and Ru3-formulations and in the G 2 /M phase (pink) between LIP-empty and CisPt (**** p < 0.0001; two-way ANOVA Tukey's test).

    Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

    Techniques: WST-1 Assay, Standard Deviation, Immunofluorescence, Staining, Control

    Cytotoxic effect of organometallic compounds in 3D parental spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B Par (A and B) and OS833 Par (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B Par (A) and OS833 Par (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Likewise, cell survival curves and IC50 values (µM) for each condition in 143B Par (B) and OS833 Par (D) spheroids are presented as the mean ± the standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test).

    Journal: Drug Delivery

    Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

    doi: 10.1080/10717544.2026.2671485

    Figure Lengend Snippet: Cytotoxic effect of organometallic compounds in 3D parental spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B Par (A and B) and OS833 Par (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B Par (A) and OS833 Par (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Likewise, cell survival curves and IC50 values (µM) for each condition in 143B Par (B) and OS833 Par (D) spheroids are presented as the mean ± the standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (**** p < 0.0001; two-way ANOVA Tukey's test).

    Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

    Techniques: Standard Deviation

    Cytotoxic effect of organometallic compounds in 3D cisplatin-resistant spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B CisPt-R (A and B) and OS833 CisPt-R (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B CisPt-R (A) and OS833 CisPt-R (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Cell survival curves and IC50 values (µM) for each condition in 143B CisPt-R (B) and OS833 CisPt-R (D) are presented as the mean ± standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (* p < 0.05; ** p < 0.01; **** p < 0.0001; two-way ANOVA Tukey's test).

    Journal: Drug Delivery

    Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

    doi: 10.1080/10717544.2026.2671485

    Figure Lengend Snippet: Cytotoxic effect of organometallic compounds in 3D cisplatin-resistant spheroids. Spheroid viability (CTG 3D assay) was measured after the treatment of 143B CisPt-R (A and B) and OS833 CisPt-R (C and D) spheroids with increasing concentrations of free and encapsulated drugs for 96 h. The effect of equivalent amounts of empty nanoparticles is shown. Representative images of 143B CisPt-R (A) and OS833 CisPt-R (C) spheroids treated with increasing concentrations of each compound are shown (scale bars = 250 µm). Cell survival curves and IC50 values (µM) for each condition in 143B CisPt-R (B) and OS833 CisPt-R (D) are presented as the mean ± standard deviation of at least eight biological replicates. Asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon) (* p < 0.05; ** p < 0.01; **** p < 0.0001; two-way ANOVA Tukey's test).

    Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

    Techniques: Standard Deviation

    Effect of free and nano-encapsulated Ru3 in CSC-enriched 3D osteosarcoma cell cultures. 143B Par cells were plated at low density in tumorsphere medium and left to form tumorspheres for 9 days before being treated for 96 h with increasing concentrations of Ru3, LIP-Ru3, and cisplatin. Treatments with the same amount of empty nanoparticles (LIP-Empty) were also included. Representative images (scale bars = 250 μm) (A), quantification of the number of tumorspheres remaining after the treatment (B), and cell viability (WST-1 assay) (C) are presented. Data is presented as the mean ± the standard deviation of independent replicates. In panel B, black asterisks indicate statistically significant differences between controls and the indicated conditions in each treatment. In panel C, asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon); (** p < 0.01; *** p < 0.001; one-way (panel B) or two-way (panel C) ANOVA Tukey's test).

    Journal: Drug Delivery

    Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

    doi: 10.1080/10717544.2026.2671485

    Figure Lengend Snippet: Effect of free and nano-encapsulated Ru3 in CSC-enriched 3D osteosarcoma cell cultures. 143B Par cells were plated at low density in tumorsphere medium and left to form tumorspheres for 9 days before being treated for 96 h with increasing concentrations of Ru3, LIP-Ru3, and cisplatin. Treatments with the same amount of empty nanoparticles (LIP-Empty) were also included. Representative images (scale bars = 250 μm) (A), quantification of the number of tumorspheres remaining after the treatment (B), and cell viability (WST-1 assay) (C) are presented. Data is presented as the mean ± the standard deviation of independent replicates. In panel B, black asterisks indicate statistically significant differences between controls and the indicated conditions in each treatment. In panel C, asterisks indicate statistically significant differences between cisplatin and Ru3 (black) or LIP-Ru3 (salmon); (** p < 0.01; *** p < 0.001; one-way (panel B) or two-way (panel C) ANOVA Tukey's test).

    Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

    Techniques: WST-1 Assay, Standard Deviation

    In vivo antitumor effect of free and nanoencapsulated metallic compounds. Established 143B CisPt-R xenografts were randomly assigned to six different groups ( n = 5 per group) and treated i.v. with vehicle (PBS, control), empty liposomes (LIP-Empty), free Ru3 (4 mg/kg, Ru3), ruthenium-loaded liposomes (4 mg/kg, LIP-Ru3), RAPTA-C (4 mg/kg), and cisplatin (4 mg/kg) once a week for 3 weeks (cumulative dose of 12 mg/kg). (A) Curves representing the mean relative tumor volume of 143B CisPt-R xenografts during the treatments. Drug efficacy expressed as the percentage of TGI is indicated. (B) Average tumor weight (left panel) and images of the tumors (right panel) at the end of the experiment (day 20 after the start of the treatment). (C) Change in the body weights of mice during the treatments. Error bars represent the SEM and asterisks indicate statistically significant differences between groups (* p < 0.05; **** p < 0.0001, two-way ANOVA Tukey's test).

    Journal: Drug Delivery

    Article Title: Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

    doi: 10.1080/10717544.2026.2671485

    Figure Lengend Snippet: In vivo antitumor effect of free and nanoencapsulated metallic compounds. Established 143B CisPt-R xenografts were randomly assigned to six different groups ( n = 5 per group) and treated i.v. with vehicle (PBS, control), empty liposomes (LIP-Empty), free Ru3 (4 mg/kg, Ru3), ruthenium-loaded liposomes (4 mg/kg, LIP-Ru3), RAPTA-C (4 mg/kg), and cisplatin (4 mg/kg) once a week for 3 weeks (cumulative dose of 12 mg/kg). (A) Curves representing the mean relative tumor volume of 143B CisPt-R xenografts during the treatments. Drug efficacy expressed as the percentage of TGI is indicated. (B) Average tumor weight (left panel) and images of the tumors (right panel) at the end of the experiment (day 20 after the start of the treatment). (C) Change in the body weights of mice during the treatments. Error bars represent the SEM and asterisks indicate statistically significant differences between groups (* p < 0.05; **** p < 0.0001, two-way ANOVA Tukey's test).

    Article Snippet: Human osteosarcoma cell line 143B (CRL-8303) was obtained from the ATCC repository (Manassas, VA, USA).

    Techniques: In Vivo, Control, Liposomes

    (A) 143B cells (osteosarcoma) show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.

    Journal: bioRxiv

    Article Title: In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma

    doi: 10.64898/2026.02.19.706776

    Figure Lengend Snippet: (A) 143B cells (osteosarcoma) show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.

    Article Snippet: Authenticated human osteosarcoma cell lines were obtained: 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), HOS (ATCC Cat# CRL-1543, RRID:CVCL_0312), MG-63 (ATCC Cat# CRL-1427, RRID:CVCL_0426), Saos-2 (ATCC Cat# HTB-85, RRID:CVCL_0548), SJSA-1 (ATCC Cat# CRL-2098, RRID:CVCL_1697), U-2 OS (ATCC Cat# HTB-96, RRID:CVCL_0042) and osteoblast cell lines hFOB 1.19 ((ATCC Cat# CRL-3602, RRID:CVCL_3708), hFOB) and NHOst (Lonza Cat #: CC-2538).

    Techniques: Control, Membrane, Derivative Assay

    Differential expression, tested using DESeq2, and pathway analysis, tested using fgsea, is shown for 143B (A, B), HOS (C, D), MG-63 (E, F), Saos-2 (G, H), SJSA1 (I, J), U-2 OS (K, L) and osteosarcoma lung metastasis 15454-307 (M, N) osteosarcoma cell lines. Volcano plots display differential expression results with log2 fold change on the x-axis and negative log10 adjusted p-value on the y-axis (A, C, E, G, I, K, M). Bar plots detail the top five most up- and down-regulated pathways (B, D, F, H, J, L, N). Both significantly different points in the volcano plot and significant pathways in the bar plots are colored by cell line; non-statistically significant points or bars are shown in gray. Legends are grouped, with the legend applying to both the volcano plot and the bar plot of the same color.

    Journal: bioRxiv

    Article Title: In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma

    doi: 10.64898/2026.02.19.706776

    Figure Lengend Snippet: Differential expression, tested using DESeq2, and pathway analysis, tested using fgsea, is shown for 143B (A, B), HOS (C, D), MG-63 (E, F), Saos-2 (G, H), SJSA1 (I, J), U-2 OS (K, L) and osteosarcoma lung metastasis 15454-307 (M, N) osteosarcoma cell lines. Volcano plots display differential expression results with log2 fold change on the x-axis and negative log10 adjusted p-value on the y-axis (A, C, E, G, I, K, M). Bar plots detail the top five most up- and down-regulated pathways (B, D, F, H, J, L, N). Both significantly different points in the volcano plot and significant pathways in the bar plots are colored by cell line; non-statistically significant points or bars are shown in gray. Legends are grouped, with the legend applying to both the volcano plot and the bar plot of the same color.

    Article Snippet: Authenticated human osteosarcoma cell lines were obtained: 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), HOS (ATCC Cat# CRL-1543, RRID:CVCL_0312), MG-63 (ATCC Cat# CRL-1427, RRID:CVCL_0426), Saos-2 (ATCC Cat# HTB-85, RRID:CVCL_0548), SJSA-1 (ATCC Cat# CRL-2098, RRID:CVCL_1697), U-2 OS (ATCC Cat# HTB-96, RRID:CVCL_0042) and osteoblast cell lines hFOB 1.19 ((ATCC Cat# CRL-3602, RRID:CVCL_3708), hFOB) and NHOst (Lonza Cat #: CC-2538).

    Techniques: Quantitative Proteomics

    Cell viability of (A) healthy osteoblasts hFOB, (B) primary osteosarcomas 143B and (C) MG-63, and (D) lung metastasis 15454-307 treated with 5 µM cycloheximide. Cell viability of (E) healthy osteoblasts NHOst, (F) healthy fibroblasts Q2148, and osteosarcomas (G) MG-63 or (H) 15454-307 treated with metformin, ONC201, or ONC206 in 5.6 mM glucose DMEM-10% FBS medium for 72 h. Cell viability of the same control cells and osteosarcoma cells, (I) hFOB, (J) NHOst, (K) Q2148, (L) 143B, (M) MG-63, (N) 15454-307 treated with 1.5 µM ONC201, or 0.15 µM ONC206 in 17 mM glucose DMEM-10%FBS medium for 72 h. Cell viability was tested using ANOVA with a post-hoc Tukey test for all comparisons. Box plots identify the median second and third quartiles and the whiskers extend to the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually.

    Journal: bioRxiv

    Article Title: In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma

    doi: 10.64898/2026.02.19.706776

    Figure Lengend Snippet: Cell viability of (A) healthy osteoblasts hFOB, (B) primary osteosarcomas 143B and (C) MG-63, and (D) lung metastasis 15454-307 treated with 5 µM cycloheximide. Cell viability of (E) healthy osteoblasts NHOst, (F) healthy fibroblasts Q2148, and osteosarcomas (G) MG-63 or (H) 15454-307 treated with metformin, ONC201, or ONC206 in 5.6 mM glucose DMEM-10% FBS medium for 72 h. Cell viability of the same control cells and osteosarcoma cells, (I) hFOB, (J) NHOst, (K) Q2148, (L) 143B, (M) MG-63, (N) 15454-307 treated with 1.5 µM ONC201, or 0.15 µM ONC206 in 17 mM glucose DMEM-10%FBS medium for 72 h. Cell viability was tested using ANOVA with a post-hoc Tukey test for all comparisons. Box plots identify the median second and third quartiles and the whiskers extend to the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually.

    Article Snippet: Authenticated human osteosarcoma cell lines were obtained: 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), HOS (ATCC Cat# CRL-1543, RRID:CVCL_0312), MG-63 (ATCC Cat# CRL-1427, RRID:CVCL_0426), Saos-2 (ATCC Cat# HTB-85, RRID:CVCL_0548), SJSA-1 (ATCC Cat# CRL-2098, RRID:CVCL_1697), U-2 OS (ATCC Cat# HTB-96, RRID:CVCL_0042) and osteoblast cell lines hFOB 1.19 ((ATCC Cat# CRL-3602, RRID:CVCL_3708), hFOB) and NHOst (Lonza Cat #: CC-2538).

    Techniques: Control

    2500 cells per well were seeded in 96 well plates with DMEM 10% FBS 12.5 mM glucose medium, and, after culturing overnight, the media was removed and replaced with the same medium with or without 25 nM antimycin A (AA) alone or with 2 mM dichloroacetate (DCA) alone or with a combination of the same concentrations of AA and DCA in (A) healthy osteoblast hFOB cells, (B) primary osteosarcoma 143B or (C) MG63 cells. (D-G) Cells were treated with a combination of 2.5 µM ONC201 (201) and 0.25 µM ONC206 (206), either with just the two-drug treatment or with the addition of 2 mM DCA, or 2 mM metformin (met) in 200 µL medium per well in (D) hFOB, (E) 143B, (F) MG-63 or (G) 15454-307 cells. (H-K) Cells were also treated with a combination of 2.5 µM ONC201, 2 mM DCA, and 2 mM met in 200 µL medium per well in (H) hFOB, (I) 143B, (J) MG-63 or (K) 15454-307 cells. After cells were cultured for 6 days, then MTT cell viability assays were performed with n = 3 biological replicate experiments. Cell viability was tested using ANOVA with a post-hoc Tukey test for all comparisons. Box plots identify the median second and third quartiles and the whiskers extend to the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually.

    Journal: bioRxiv

    Article Title: In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma

    doi: 10.64898/2026.02.19.706776

    Figure Lengend Snippet: 2500 cells per well were seeded in 96 well plates with DMEM 10% FBS 12.5 mM glucose medium, and, after culturing overnight, the media was removed and replaced with the same medium with or without 25 nM antimycin A (AA) alone or with 2 mM dichloroacetate (DCA) alone or with a combination of the same concentrations of AA and DCA in (A) healthy osteoblast hFOB cells, (B) primary osteosarcoma 143B or (C) MG63 cells. (D-G) Cells were treated with a combination of 2.5 µM ONC201 (201) and 0.25 µM ONC206 (206), either with just the two-drug treatment or with the addition of 2 mM DCA, or 2 mM metformin (met) in 200 µL medium per well in (D) hFOB, (E) 143B, (F) MG-63 or (G) 15454-307 cells. (H-K) Cells were also treated with a combination of 2.5 µM ONC201, 2 mM DCA, and 2 mM met in 200 µL medium per well in (H) hFOB, (I) 143B, (J) MG-63 or (K) 15454-307 cells. After cells were cultured for 6 days, then MTT cell viability assays were performed with n = 3 biological replicate experiments. Cell viability was tested using ANOVA with a post-hoc Tukey test for all comparisons. Box plots identify the median second and third quartiles and the whiskers extend to the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually.

    Article Snippet: Authenticated human osteosarcoma cell lines were obtained: 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), HOS (ATCC Cat# CRL-1543, RRID:CVCL_0312), MG-63 (ATCC Cat# CRL-1427, RRID:CVCL_0426), Saos-2 (ATCC Cat# HTB-85, RRID:CVCL_0548), SJSA-1 (ATCC Cat# CRL-2098, RRID:CVCL_1697), U-2 OS (ATCC Cat# HTB-96, RRID:CVCL_0042) and osteoblast cell lines hFOB 1.19 ((ATCC Cat# CRL-3602, RRID:CVCL_3708), hFOB) and NHOst (Lonza Cat #: CC-2538).

    Techniques: Cell Culture

    (A-B) Looking at pediatric cancers with Clp alterations, (A) 1.15% of osteosarcomas have ClpP alterations and (B) 9.20% of osteosarcomas have ClpX alterations. Cancers are given on the x-axis with the y-axis the percentage of alterations across all patients in either (A) ClpP or (B) ClpX. Color indicates the alteration type. (C-E) 90% confluent hFOB or 143B cells in 100 mm Petri dishes were treated with increasing doses of ONC201 or ONC206 indicated in 5.6 mM glucose DMEM, after 24 h, cells were collected and lysed in RIPA buffer. (C) Western immunoblots following SDS-PAGE (immunoblots for ClpP and ClpX are in supplemental figure S4) were imaged with anti-ClpP o r ClpX and anti-CS antibodies, resulting band intensities for the untreated and highest dose of each drug were analyzed by ImageJ, normalized to CS and relative to hFOB for ClpP (D) and ClpX (E) . (F) The differential expression results from 143B cells treated with ONC201 or ONC206 were used to evaluate the overlap in expression changes using an UpSet plot, where the bars show the number of genes changed and a single dot underneath for ONC201 and ONC206, respectively, and the line showing the number of significantly differentially expressed genes in common with both treatments. Pathway analysis, done with over-representation analysis (ORA) in WebGestaltR, on gene expression changes unique to (G) ONC201 alone, (H) ONC206 alone, (I) or common to both versions of the drug. Pathway analysis bar plots give the top five most up- and down-regulated pathways colored by treatment type with non-statistically significant pathways in gray (G-I) .

    Journal: bioRxiv

    Article Title: In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma

    doi: 10.64898/2026.02.19.706776

    Figure Lengend Snippet: (A-B) Looking at pediatric cancers with Clp alterations, (A) 1.15% of osteosarcomas have ClpP alterations and (B) 9.20% of osteosarcomas have ClpX alterations. Cancers are given on the x-axis with the y-axis the percentage of alterations across all patients in either (A) ClpP or (B) ClpX. Color indicates the alteration type. (C-E) 90% confluent hFOB or 143B cells in 100 mm Petri dishes were treated with increasing doses of ONC201 or ONC206 indicated in 5.6 mM glucose DMEM, after 24 h, cells were collected and lysed in RIPA buffer. (C) Western immunoblots following SDS-PAGE (immunoblots for ClpP and ClpX are in supplemental figure S4) were imaged with anti-ClpP o r ClpX and anti-CS antibodies, resulting band intensities for the untreated and highest dose of each drug were analyzed by ImageJ, normalized to CS and relative to hFOB for ClpP (D) and ClpX (E) . (F) The differential expression results from 143B cells treated with ONC201 or ONC206 were used to evaluate the overlap in expression changes using an UpSet plot, where the bars show the number of genes changed and a single dot underneath for ONC201 and ONC206, respectively, and the line showing the number of significantly differentially expressed genes in common with both treatments. Pathway analysis, done with over-representation analysis (ORA) in WebGestaltR, on gene expression changes unique to (G) ONC201 alone, (H) ONC206 alone, (I) or common to both versions of the drug. Pathway analysis bar plots give the top five most up- and down-regulated pathways colored by treatment type with non-statistically significant pathways in gray (G-I) .

    Article Snippet: Authenticated human osteosarcoma cell lines were obtained: 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), HOS (ATCC Cat# CRL-1543, RRID:CVCL_0312), MG-63 (ATCC Cat# CRL-1427, RRID:CVCL_0426), Saos-2 (ATCC Cat# HTB-85, RRID:CVCL_0548), SJSA-1 (ATCC Cat# CRL-2098, RRID:CVCL_1697), U-2 OS (ATCC Cat# HTB-96, RRID:CVCL_0042) and osteoblast cell lines hFOB 1.19 ((ATCC Cat# CRL-3602, RRID:CVCL_3708), hFOB) and NHOst (Lonza Cat #: CC-2538).

    Techniques: Western Blot, SDS Page, Quantitative Proteomics, Expressing, Gene Expression